Friday 16 October 2026
Export CDXS’s income statement to Excel — free account
Codexis, Inc.
CDXS Healthcare Biotechnology
Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.
1.25
0.11
−8.09%
Follow CDXS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 3 | 3 | 4 | 3 | 3 | 2 | 4 | 2 | 3 |
P/S ratio |
2.02 | 5.90 | 3.03 | 2.20 | 19.27 | 18.76 | 13.20 | 14.39 | 7.53 | 3.74 |
Altman Z-Score |
(4.75) | (3.02) | (3.23) | 0.01 | 13.32 | 13.59 | 10.21 | 17.98 | (0.29) | (3.62) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 101.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(11.56) | (10.79) | (10.64) | (2.00) | (0.22) | 2.07 | (1.16) | (7.83) | (18.69) | (24.38) |
Beneish M-Score |
(3.57) | (3.19) | (4.02) | (3.12) | (1.91) | (2.44) | (1.64) | (2.07) | (2.86) | (3.52) |
P/Operating CF |
7.07 | (21.26) | (19.26) | 62.06 | 3,059.15 | (868.52) | (246.88) | (1,210.87) | 49.40 | 35.41 |
P/B ratio |
2.81 | 5.23 | 2.45 | 2.11 | 12.28 | 7.62 | 8.57 | 15.48 | 15.35 | 9.57 |
Price to Tangible BV |
2.96 | 5.43 | 2.53 | 2.16 | 12.53 | 7.77 | 8.84 | 16.43 | 17.68 | 11.53 |
EV/Sales |
1.47 | 5.14 | 2.28 | 1.65 | 18.57 | 16.91 | 12.24 | 13.51 | 6.92 | 3.37 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(5.34) | (6.17) | (3.04) | 20.29 | (136.34) | (70.91) | (66.69) | (58.10) | (39.55) | (88.43) |
EV/FCF |
(4.34) | (5.69) | (2.84) | 76.16 | (69.33) | (57.76) | (51.43) | (48.57) | (35.56) | (60.78) |
Quick Ratio |
3.51 | 3.74 | 2.37 | 3.12 | 4.51 | 7.03 | 7.17 | 3.67 | 1.72 | 2.03 |
Current Ratio |
3.82 | 4.18 | 2.61 | 3.32 | 4.85 | 7.38 | 7.42 | 3.77 | 1.81 | 2.20 |
Net Debt/EBITDA |
1.11 | 0.87 | 1.13 | 3.09 | 4.41 | 6.63 | 8.28 | 5.22 | 1.39 | 4.57 |
Debt/Assets |
27.14% | 19.40% | 0.00% | 15.29% | 17.68% | 10.07% | 16.74% | 0.12% | 1.42% | 2.48% |
Debt/Equity |
0.79 | 0.43 | 0.00 | 0.26 | 0.27 | 0.13 | 0.24 | 0.00 | 0.03 | 0.05 |
Asset Turnover |
0.47 | 0.42 | 0.36 | 0.56 | 0.45 | 0.37 | 0.60 | 0.91 | 1.12 | 1.22 |
Operating CF/Net income |
0.44 | 0.76 | 0.69 | (0.34) | 0.67 | 0.69 | 1.05 | 1.30 | 0.38 | 0.22 |
Capex/Depreciation |
(0.63) | (0.62) | (0.37) | (0.81) | (2.32) | (0.82) | (0.82) | (2.41) | (0.94) | (0.19) |
Interest Coverage |
(8.67) | (5.63) | (5.55) | 281.30 | (49.45) | (59.06) | (9.75) | (16.83) | (156.26) | (142.73) |
| (74.88%) | (85.03%) | (65.89%) | (21.73%) | (12.72%) | (17.42%) | (14.75%) | (26.91%) | (105.38%) | (40.77%) | |
| (29.63%) | (45.72%) | (39.41%) | (13.52%) | (9.09%) | (12.95%) | (10.45%) | (16.37%) | (51.52%) | (21.32%) | |
ROIC |
(218.36%) | (167.23%) | (202.78%) | (31.79%) | (15.66%) | (35.88%) | (19.95%) | (209.91%) | 0.00% | (719.42%) |
Return on Tangible Assets |
(52.03%) | (73.08%) | (104.26%) | (24.62%) | (14.20%) | (14.20%) | (11.36%) | (19.83%) | (100.41%) | (50.30%) |
Average Days of Receivables |
52.86 | 89.24 | 99.46 | 102.07 | 115.31 | 130.88 | 101.99 | 81.12 | 86.10 | 44.28 |
Research and Development Expense of Revenue |
74.31% | 77.96% | 83.95% | 57.80% | 53.38% | 63.98% | 49.48% | 49.47% | 59.29% | 45.52% |
Selling, General and Administrative Expense of Revenue |
66.88% | 92.93% | 75.92% | 37.64% | 47.08% | 50.75% | 46.02% | 48.34% | 57.99% | 52.05% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.06 | 0.09 |
Share Based Compensation of Revenue |
13.67% | 22.05% | 14.22% | 10.48% | 11.07% | 11.19% | 10.14% | 13.02% | 14.18% | 11.62% |
Graham Net Nets |
0.00 | 0.05 | 0.20 | 0.19 | 0.04 | 0.10 | 0.08 | 0.05 | 0.04 | 0.06 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(31.90%) | (18.87%) | (35.58%) | (10.92%) | (1.09%) | (1.83%) | (1.34%) | (1.32%) | (6.13%) | (4.44%) |
Free Cash Flow Yield |
(16.79%) | (15.32%) | (26.49%) | 0.99% | (1.39%) | (1.56%) | (1.80%) | (1.93%) | (2.58%) | (1.48%) |
Revenue per Share |
0.81 | 0.81 | 1.03 | 2.12 | 1.62 | 1.16 | 1.21 | 1.16 | 1.08 | 1.20 |
Operating CF per Share |
(0.22) | (0.67) | (0.77) | 0.17 | (0.22) | (0.28) | (0.22) | (0.27) | (0.19) | (0.05) |
Capex per Share |
(0.05) | (0.06) | (0.05) | (0.13) | (0.21) | (0.06) | (0.07) | (0.05) | (0.02) | (0.02) |
Free Cash Flow per Share |
(0.27) | (0.73) | (0.83) | 0.05 | (0.43) | (0.34) | (0.29) | (0.32) | (0.21) | (0.07) |
Cash per Share |
0.90 | 1.01 | 0.96 | 1.75 | 1.82 | 2.54 | 1.61 | 1.02 | 0.68 | 0.47 |
Shareholders Equity per Share |
0.58 | 0.91 | 1.27 | 2.22 | 2.55 | 2.87 | 1.87 | 1.08 | 0.53 | 0.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.58 | 0.91 | 1.27 | 2.22 | 2.55 | 2.87 | 1.87 | 1.08 | 0.53 | 0.47 |
Free Cash Flow |
(23.84) | (53.63) | (56.30) | 3.01 | (28.06) | (20.21) | (16.29) | (16.86) | (9.74) | (2.71) |
Working Capital |
71.50 | 75.12 | 57.64 | 113.83 | 128.52 | 159.44 | 98.82 | 50.09 | 20.09 | 14.86 |
Capital Expenditures |
(4.47) | (4.22) | (3.67) | (8.28) | (13.79) | (3.75) | (3.73) | (2.77) | (0.98) | (0.85) |
Net Current Asset Value |
(0.45) | 16.69 | 43.52 | 57.30 | 79.90 | 132.88 | 70.65 | 45.22 | 15.96 | 10.68 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.07 | 0.05 | 0.06 | 0.13 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.54 | 0.48 | 0.64 | 0.45 | 0.28 | 0.47 | 0.73 | 0.24 | 0.37 | 2.11 |
Cash ROIC |
(14.08%) | (31.58%) | (36.98%) | 1.01% | (8.62%) | (5.89%) | (7.35%) | (15.41%) | (17.23%) | (6.90%) |
Accounts Receivable Turnover |
5.70 | 3.53 | 2.42 | 3.86 | 3.62 | 3.15 | 4.20 | 4.80 | 5.64 | 7.37 |
Accounts Payable Turnover |
4.25 | 3.71 | 2.79 | 12.19 | 7.45 | 4.92 | 5.51 | 3.83 | 3.68 | 2.56 |
Inventory Turnover |
5.16 | 7.26 | 5.43 | 23.85 | 20.91 | 20.59 | 32.57 | 15.53 | 15.40 | 10.74 |
Average Days of Payables |
60.74 | 63.60 | 169.46 | 31.15 | 49.22 | 78.89 | 61.20 | 88.21 | 90.31 | 158.38 |
Days of Inventory on Hand |
71.02 | 40.31 | 76.51 | 19.47 | 19.06 | 25.60 | 8.66 | 17.04 | 26.39 | 30.88 |
Average Receivables |
12.35 | 16.81 | 28.94 | 35.93 | 28.93 | 21.95 | 16.30 | 12.63 | 8.86 | 6.63 |
Average Payables |
2.20 | 4.39 | 4.60 | 3.12 | 2.98 | 2.80 | 2.84 | 3.30 | 3.89 | 3.82 |
Average Inventory |
1.81 | 2.24 | 2.36 | 1.59 | 1.06 | 0.67 | 0.48 | 0.81 | 0.93 | 0.91 |
Average Assets |
148.40 | 142.79 | 193.48 | 248.39 | 234.01 | 185.36 | 114.18 | 66.45 | 44.64 | 40.15 |
Average Common Equity |
58.73 | 76.77 | 115.71 | 154.59 | 167.25 | 137.81 | 80.91 | 40.43 | 21.82 | 20.99 |
Columns are period end dates